FDA Removes Partial Clinical Hold from Idenix Pharma's (IDIX) IDX184
Tweet
Share
E-mailGet Alerts IDIX Hot Sheet
Join SI Premium – FREE
Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) today announced that it has received notification from the U.S. FDA that the partial clinical hold on IDX184 has been removed and that the Company's 12-week phase IIb study evaluating IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV) may continue.
IDX184 has demonstrated a high barrier to resistance in vitro and potent antiviral activity in both preclinical and clinical studies. Recently announced interim phase IIb data demonstrated favorable antiviral activity and no serious adverse events.
IDX184 has demonstrated a high barrier to resistance in vitro and potent antiviral activity in both preclinical and clinical studies. Recently announced interim phase IIb data demonstrated favorable antiviral activity and no serious adverse events.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Hinge Health signs $86M office lease in San Francisco
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
